Introduction: Cancer is a Non-Communicable Chronic Disease (NCD) characterized by a group of multifactorial diseases, including viral infections. Human Papillomaviruses (HPV) are associated with the occurrence of malignant neoplasms as well as other health conditions, such as cutaneous and genital warts. HPV belongs to a large family of non-enveloped, double-stranded DNA viruses, with over 220 identified types, and is involved in various carcinogenesis processes, including head and neck cancer (HNC), cervical, anal, vulvar, and penile cancers. Loop-mediated isothermal amplification (PCR-LAMP) requires minimal instrumentation to synthesize DNA/RNA in vitro. The technique consists of two phases—cyclic and non-cyclic—and requires the design of specific primers: BIP (Backward Inner Primer), FIP (Forward Inner Primer), B3P (Backward 3 Primer) and F3P (Forward 3 Primer). LAMP emerges as an alternative for molecular diagnostics, enabling testing in resource-limited settings in a shorter time compared to conventional PCR. This allows sample collection and diagnosis without the need for large laboratory facilities, characterizing a Point-of-Care approach. Objectives: To develop a loop-mediated isothermal amplification (PCR-LAMP) technique for the rapid diagnosis of HPV. Methods: Biological samples from HNC patients were collected through oral swabs, with smears taken from multiple points in the oral cavity and subsequently stored at -80ºC. Viral DNA extraction followed a protocol using PBS (Phosphate-Buffered Saline) and Proteinase K. The quantification of viral DNA samples was performed using the Qubit 4.0 platform. Loop-mediated isothermal amplification (LAMP) was carried out using the Bst2.0 DNA Polymerase kit (Cellco). Target sequences were selected from the NCBI (National Center for Biotechnology Information) database, aligned, and stable regions were identified. The LAMP primers were designed using UGENE 49.1 and LAMP Primer Explorer V.4 software. PCR-LAMP reactions were performed in a thermocycler at 60ºC for 60 minutes and 80ºC for 10 minutes. Results were interpreted through electrophoresis, with fluorescence visualization used to determine the method's sensitivity. Results: Initial amplification verification was observed through electrophoresis, where standardization primers (?-Actin) displayed bands corresponding to the expected molecular weight, as did the HPV primers. Rapid diagnostic visualization was successfully achieved by adding the SYBR Safe 10X intercalating dye—which binds to double-stranded DNA—to the PCR-LAMP product, followed by UV light exposure for detection. Positive samples and negative controls were distinguished by the intensity of emitted fluorescence, which varied according to the concentration of viral DNA present. Positive results were obtained with 10 ng/mL of DNA. Conclusion: The PCR-LAMP technique demonstrated fidelity and specificity to HPV, regardless of type, providing easily visualized results and optimizing sample collection and processing time. This method is accessible for large-scale screening programs due to its low operational cost, embodying the key features of a Point-of-Care approach.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/